• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

四纳米抗体Fc 二聚体的生化特性、结构和细胞内化。

Biochemistry, structure, and cellular internalization of a four nanobody-bearing Fc dimer.

机构信息

Pole d'Expertise Biotechnologie, Chimie, Biologie, Institut de Recherches Servier, Croissy-sur-Seine, France.

Lumedix, Palaiseau, France.

出版信息

Protein Sci. 2021 Sep;30(9):1946-1957. doi: 10.1002/pro.4147. Epub 2021 Jun 17.

DOI:10.1002/pro.4147
PMID:34117809
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8376420/
Abstract

VHH stands for the variable regions of heavy chain only of camelid IgGs. The VHH family forms a set of interesting proteins derived from antibodies that maintain their capacity to recognize the antigen, despite their relatively small molecular weight (in the 12,000 Da range). Continuing our exploration of the possibilities of those molecules, we chose to design alternative molecules with maintained antigen recognition, but enhanced capacity, by fusing four VHH with one Fc, the fragment crystallizable region of antibodies. In doing so, we aimed at having a molecule with superior quantitative antigen recognition (×4) while maintaining its size below the 110 kDa. In the present paper, we described the building of those molecules that we coined VHH -Fc-VHH . The structure of VHH -Fc-VHH in complex with HER2 antigen was determined using electronic microscopy and modeling. The molecule is shown to bind four HER2 proteins at the end of its flexible arms. VHH -Fc-VHH also shows an internalization capacity via HER2 receptor superior to the reference anti-HER2 monoclonal antibody, Herceptin®, and to a simple fusion of two VHH with one Fc (VHH -Fc). This new type of molecules, VHH -Fc-VHH , could be an interesting addition to the therapeutic arsenal with multiple applications, from diagnostic to therapy.

摘要

VHH 代表仅重链可变区的骆驼科 IgG。VHH 家族形成了一组有趣的蛋白质,它们来源于抗体,尽管它们的相对分子量较小(在 12000 Da 范围内),但仍保持识别抗原的能力。为了继续探索这些分子的可能性,我们选择设计具有保持抗原识别能力但增强的能力的替代分子,通过将四个 VHH 与一个 Fc(抗体的结晶片段)融合。这样,我们的目标是拥有一种具有优异定量抗原识别能力(×4)的分子,同时保持其大小低于 110 kDa。在本文中,我们描述了构建这些我们称之为 VHH-Fc-VHH 的分子。使用电子显微镜和建模确定了 VHH-Fc-VHH 与 HER2 抗原复合物的结构。该分子显示在其柔性臂的末端结合四个 HER2 蛋白。VHH-Fc-VHH 还通过 HER2 受体显示出优于参考抗 HER2 单克隆抗体赫赛汀(Herceptin®)和两个 VHH 与一个 Fc(VHH-Fc)简单融合的内化能力。这种新型分子 VHH-Fc-VHH 可以成为治疗武器库的一个有趣补充,具有多种应用,从诊断到治疗。

相似文献

1
Biochemistry, structure, and cellular internalization of a four nanobody-bearing Fc dimer.四纳米抗体Fc 二聚体的生化特性、结构和细胞内化。
Protein Sci. 2021 Sep;30(9):1946-1957. doi: 10.1002/pro.4147. Epub 2021 Jun 17.
2
In vivo neutralization of α-cobratoxin with high-affinity llama single-domain antibodies (VHHs) and a VHH-Fc antibody.体内中和α-眼镜蛇毒素的高亲和力羊驼单域抗体(VHH)和 VHH-Fc 抗体。
PLoS One. 2013 Jul 22;8(7):e69495. doi: 10.1371/journal.pone.0069495. Print 2013.
3
Generation, biochemical characterizations and validation of potent nanobodies derived from alpaca specific for human receptor of advanced glycation end product.从羊驼中特异性针对人晚期糖基化终产物受体的纳米抗体的产生、生化特性分析及其验证。
Biochem Biophys Res Commun. 2021 Dec 3;581:38-45. doi: 10.1016/j.bbrc.2021.10.005. Epub 2021 Oct 8.
4
Covalently dimerized Camelidae antihuman TNFa single-domain antibodies expressed in yeast Pichia pastoris show superior neutralizing activity.酵母毕赤酵母中表达的共价二聚化骆驼科抗人 TNFa 单域抗体具有优异的中和活性。
Appl Microbiol Biotechnol. 2013 Oct;97(19):8547-58. doi: 10.1007/s00253-012-4639-2. Epub 2013 Jan 17.
5
Fusion of an Fc chain to a VHH boosts the accumulation levels in Arabidopsis seeds.Fc 链融合到 VHH 可提高拟南芥种子中的积累水平。
Plant Biotechnol J. 2013 Oct;11(8):1006-16. doi: 10.1111/pbi.12094. Epub 2013 Aug 6.
6
Fcab-HER2 Interaction: a Ménage à Trois. Lessons from X-Ray and Solution Studies.Fcab与HER2的相互作用:三方关系。来自X射线和溶液研究的经验教训。
Structure. 2017 Jun 6;25(6):878-889.e5. doi: 10.1016/j.str.2017.04.014. Epub 2017 May 18.
7
Full-length recombinant antibodies from : production, characterization, effector function (Fc) engineering, and clinical evaluation.全长重组抗体:生产、表征、效应功能(Fc)工程和临床评估。
MAbs. 2022 Jan-Dec;14(1):2111748. doi: 10.1080/19420862.2022.2111748.
8
T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.表达VHH导向的寡克隆嵌合HER2抗原受体的T细胞:迈向肿瘤导向的寡克隆T细胞疗法。
Biochim Biophys Acta. 2014 Jan;1840(1):378-86. doi: 10.1016/j.bbagen.2013.09.029. Epub 2013 Sep 27.
9
Characterization of the Fc-III-4C-based recombinant protein expression system by using carbonic anhydrase as the model protein.以碳酸酐酶为模型蛋白,对基于 Fc-III-4C 的重组蛋白表达系统进行表征。
Protein Expr Purif. 2021 Jan;177:105761. doi: 10.1016/j.pep.2020.105761. Epub 2020 Sep 19.
10
Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK.使用两种不同的残留标记物SGMIB和IB-Mal-D-GEEEK对放射性碘化后的抗p185(HER2)(scFv-C(H)2-C(H)3)2片段进行评估。
Nucl Med Biol. 2009 Aug;36(6):671-80. doi: 10.1016/j.nucmedbio.2009.04.002.

引用本文的文献

1
Research Progress on the Application of Neutralizing Nanobodies in the Prevention and Treatment of Viral Infections.中和纳米抗体在病毒感染防治中的应用研究进展
Microorganisms. 2025 Jun 11;13(6):1352. doi: 10.3390/microorganisms13061352.

本文引用的文献

1
Design, synthesis, and computational validation of novel compounds selectively targeting HER2-expressing breast cancer.新型化合物的设计、合成及针对 HER2 表达型乳腺癌的计算验证。
Bioorg Med Chem Lett. 2020 Dec 15;30(24):127658. doi: 10.1016/j.bmcl.2020.127658. Epub 2020 Oct 29.
2
Multimeric single-domain antibody complexes protect against bunyavirus infections.多聚体单域抗体复合物可预防布尼亚病毒感染。
Elife. 2020 Apr 21;9:e52716. doi: 10.7554/eLife.52716.
3
The year's new drugs and biologics 2019.2019年的新型药物和生物制品
Drugs Today (Barc). 2020 Jan;56(1):47-103. doi: 10.1358/dot.2020.56.1.3129707.
4
The role of antibody delivery formation in cancer therapy.抗体递送形式在癌症治疗中的作用。
J Drug Target. 2020 Jul;28(6):574-584. doi: 10.1080/1061186X.2020.1728537. Epub 2020 Feb 18.
5
Evaluating single-domain antibodies as carriers for targeted vaccine delivery to the small intestinal epithelium.评估单域抗体作为靶向疫苗递送至小肠上皮细胞的载体。
J Control Release. 2020 May 10;321:416-429. doi: 10.1016/j.jconrel.2020.01.033. Epub 2020 Jan 22.
6
Aptamers Chemistry: Chemical Modifications and Conjugation Strategies.适体化学:化学修饰与偶联策略。
Molecules. 2019 Dec 18;25(1):3. doi: 10.3390/molecules25010003.
7
Simplified monomeric VHH-Fc antibodies provide new opportunities for passive immunization.单体化 VH H-Fc 抗体为被动免疫提供了新的机会。
Curr Opin Biotechnol. 2020 Feb;61:96-101. doi: 10.1016/j.copbio.2019.11.006. Epub 2019 Dec 4.
8
VHH characterization.Recombinant VHHs: Production, characterization and affinity.VHH 表征。重组 VHH:生产、表征和亲和力。
Anal Biochem. 2020 Jan 15;589:113491. doi: 10.1016/j.ab.2019.113491. Epub 2019 Oct 30.
9
VHH characterization. Comparison of recombinant with chemically synthesized anti-HER2 VHH.VHH 表征。重组抗 HER2 VHH 与化学合成 VHH 的比较。
Protein Sci. 2019 Oct;28(10):1865-1879. doi: 10.1002/pro.3712. Epub 2019 Aug 29.
10
Antibody Therapy for the Control of Viral Diseases: An Update.抗体治疗在病毒病防治中的应用:最新进展。
Curr Pharm Biotechnol. 2019;20(13):1108-1121. doi: 10.2174/1389201020666190809112704.